Axsome Therapeutics Inc (AXSM): MarketCap $95M /Cash $50M /5x Phase 3 =...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	128
Posts	2150
Boards Moderated	1
Alias Born	12/27/2007

BioSpecialist

Re: None

Thursday, 03/30/2017 12:16:29 PM

Thursday, March 30, 2017 12:16:29 PM

MarketCap $95M /Cash $50M /5x Phase 3 = Definitely one of the most undervalued Biotech you can get in USA

Market Cap: $95 Million
Cash: $50 Million
Price: 4.17

http://biopharmcatalyst.com/companies/company-pipeline-database#sort=company

AXS-02 COAST-1 Knee Osteoarthritis Associated with Bone Marrow Lesions Phase 3 Phase 3 commenced March 2016. Interim analysis due 3Q 2017.

AXS-02 CREATE-1 Complex regional pain syndrome (CRPS) Phase 3 Initiated July 2015. Expect to complete trial by end of 2017 with interim efficacy analysis due 4Q 2017.

AXS-02 Chronic Low Back Pain Associated with Modic Changes Phase 3 Phase 3 initiation contingent upon resources.

AXS-05 Agitation in patients with Alzheimer’s disease (AD) Phase 2/3 Phase 2/3 to be initiated 2Q 2017.

AXS-05 STRIDE-1 Treatment resistant depression Phase 3 Phase 3 initiated March 2016. Top-line data due 1Q 2018.